Three Seasons Wealth LLC Grows Stock Holdings in Exelixis, Inc. $EXEL

Three Seasons Wealth LLC lifted its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 345.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 59,519 shares of the biotechnology company’s stock after acquiring an additional 46,162 shares during the period. Exelixis makes up 1.0% of Three Seasons Wealth LLC’s portfolio, making the stock its 28th biggest position. Three Seasons Wealth LLC’s holdings in Exelixis were worth $2,553,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in EXEL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Exelixis by 81.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock valued at $1,592,000 after purchasing an additional 19,407 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Exelixis by 4.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock valued at $54,153,000 after purchasing an additional 68,133 shares during the period. Focus Partners Wealth lifted its stake in shares of Exelixis by 83.4% during the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock worth $1,420,000 after purchasing an additional 17,483 shares in the last quarter. Geneos Wealth Management Inc. lifted its stake in shares of Exelixis by 134.3% during the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 944 shares in the last quarter. Finally, Sivia Capital Partners LLC boosted its position in shares of Exelixis by 23.8% in the second quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock worth $633,000 after buying an additional 2,764 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on EXEL shares. Royal Bank Of Canada increased their target price on Exelixis from $43.00 to $46.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. Wall Street Zen upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Morgan Stanley reaffirmed a “positive” rating on shares of Exelixis in a research report on Monday, June 22nd. HC Wainwright reiterated a “buy” rating and set a $56.00 price objective on shares of Exelixis in a research note on Thursday, July 2nd. Finally, Wells Fargo & Company boosted their target price on shares of Exelixis from $40.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Monday. Nine analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Exelixis currently has an average rating of “Hold” and an average target price of $48.80.

Exelixis Stock Performance

Shares of NASDAQ EXEL opened at $55.55 on Thursday. Exelixis, Inc. has a 1 year low of $33.76 and a 1 year high of $57.57. The firm has a market cap of $13.96 billion, a price-to-earnings ratio of 18.46, a PEG ratio of 1.61 and a beta of 0.42. The stock’s 50-day simple moving average is $52.30 and its 200-day simple moving average is $46.66.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.75 by $0.12. The business had revenue of $610.81 million for the quarter, compared to analysts’ expectations of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The company’s revenue was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.55 earnings per share. As a group, research analysts predict that Exelixis, Inc. will post 3.16 EPS for the current year.

Insider Activity at Exelixis

In other news, CFO Christopher J. Senner sold 34,901 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $50.00, for a total transaction of $1,745,050.00. Following the completion of the sale, the chief financial officer owned 952,317 shares of the company’s stock, valued at approximately $47,615,850. This trade represents a 3.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jack L. Wyszomierski sold 3,925 shares of Exelixis stock in a transaction on Monday, June 1st. The stock was sold at an average price of $50.55, for a total transaction of $198,408.75. Following the completion of the sale, the director owned 284,384 shares of the company’s stock, valued at approximately $14,375,611.20. This trade represents a 1.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 219,170 shares of company stock worth $10,620,641 over the last ninety days. Company insiders own 2.60% of the company’s stock.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.